Department of Medical and Clinical Pharmacology, University Hospital Center, CERPOP INSERM UMR 1295 - SPHERE team, 37 allées Jules Guesde, 31000, Toulouse, France.
Department of Medical and Clinical Pharmacology, University Hospital Center, CERPOP INSERM UMR 1295 - SPHERE team, 37 allées Jules Guesde, 31000, Toulouse, France.
Respir Med. 2024 Oct;232:107741. doi: 10.1016/j.rmed.2024.107741. Epub 2024 Jul 24.
Respiratory tract disorders are common in children. However, there is no available data on the prescription of respiratory medications for children in France. This study aimed to provide an overview of medications for obstructive airway diseases prescriptions for children during the initial ten years of their lives within POMME, a French population-based cohort of children.
This longitudinal, population-based study used data from the French POMME birth cohort, comprising children born in Haute Garonne between July 2010 and June 2011. Anonymous medical information, including medication reimbursement data, was collected between ages 0 and 10 years. Exposure was defined as at least one prescription for respiratory medications (ATC code R03*), focusing on specific subclasses. Data were analyzed by age, season, and prescribing physicians' specialties.
Out of 5956 children, 4951 (83.1 %) received respiratory medication prescriptions. Inhaled corticosteroids (ICSs) were the most prescribed (95.3 %), followed by short-acting β2-agonists (68.8 %). The number of prescriptions increased with age, except for ICSs alone, which peaked between 6 months and 2 years. The average number of prescriptions per child was relatively low.
This study highlighted high prescription rates of respiratory medications in children under 10 years, with ICSs being the most prevalent. While these medications are primarily intended for asthma management, the findings suggested a significant proportion of off-label prescriptions, especially in young children. Further research and clinical guidance are warranted to ensure appropriate medication use in the pediatric population.
呼吸道疾病在儿童中很常见。然而,法国目前尚无儿童呼吸道药物处方的相关数据。本研究旨在通过法国基于人群的 POMME 队列中儿童的初始十年内,为儿童的气道阻塞性疾病药物处方提供概述。
这是一项纵向、基于人群的研究,使用了法国 POMME 出生队列的数据,该队列包含 2010 年 7 月至 2011 年 6 月期间在上加龙省出生的儿童。0 至 10 岁期间收集了匿名的医疗信息,包括药物报销数据。暴露定义为至少有一次呼吸道药物处方(ATC 代码 R03*),重点关注特定亚类。根据年龄、季节和开处方医生的专业对数据进行了分析。
在 5956 名儿童中,有 4951 名(83.1%)接受了呼吸道药物处方。吸入性皮质类固醇(ICSs)是最常开的药物(95.3%),其次是短效β2-受体激动剂(68.8%)。除了 ICS 外,随着年龄的增长,处方数量增加,ICS 达到峰值的年龄在 6 个月至 2 岁之间。每个儿童的平均处方数量相对较低。
本研究强调了 10 岁以下儿童呼吸道药物处方率高,ICS 是最常见的药物。虽然这些药物主要用于哮喘管理,但研究结果表明存在大量的标签外处方,尤其是在年幼的儿童中。需要进一步的研究和临床指导,以确保儿科人群中适当使用药物。